Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases and cancer.
Company Growth (employees)
Type
Public
HQ
Boston, US
Founded
1989
Size (employees)
2,150 (est)
Website
vrtx.com
Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US

Key People/Management at Vertex Pharmaceuticals

Jeffrey Leiden

Jeffrey Leiden

Chairman, President and CEO
David Altshuler

David Altshuler

Executive Vice President, Global Research and Chief Scientific Officer
Stuart Arbuckle

Stuart Arbuckle

Executive Vice President and Chief Commercial Officer
Jeffrey Chodakewitz

Jeffrey Chodakewitz

Executive Vice President, Global Medicines Development, Medical Affairs, and Chief Medical Officer
Michael Parini

Michael Parini

Executive Vice President, Chief Legal and Administrative Officer
Amit Sachdev

Amit Sachdev

Executive Vice President and Chief Regulatory Officer
Ian Smith

Ian Smith

Executive Vice President, Chief Operating Officer
Simon Bedson

Simon Bedson

Senior Vice President and General Manager, International Commercial Operations
D.Phil Mark Bunnage

D.Phil Mark Bunnage

Senior Vice President and Site Head, Boston Research
Stephanie Franklin

Stephanie Franklin

Senior Vice President and Chief Human Resources Officer
Tom Graney

Tom Graney

Senior Vice President and Chief Financial Officer
Patricia Hurter

Patricia Hurter

Senior Vice President, Pharmaceutical and Preclinical Sciences
Reshma Kewalramani

Reshma Kewalramani

Senior Vice President, Clinical Development and Medical Affairs
Paul Negulescu

Paul Negulescu

Senior Vice President and Site Head, San Diego Research
Mario Saltarelli

Mario Saltarelli

Senior Vice President, Early Development and Neurology
Damian Wilmot

Damian Wilmot

Senior Vice President, Chief Risk and Compliance Officer
Gillian Burgess

Gillian Burgess

Vice President and Site Head, U.K. Research
Michael Partridge

Michael Partridge

Vice President, Investor Relations

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has an office in Boston
Boston, US (HQ)
50 Northern Ave
Show all (1)

Vertex Pharmaceuticals Financials and Metrics

Vertex Pharmaceuticals Financials

Vertex Pharmaceuticals's revenue was reported to be $2.5 b in FY, 2017
USD

Revenue (FY, 2017)

2.5 b

Net income (FY, 2017)

91.6 m

EBIT (FY, 2017)

123.2 m

Market capitalization (16-Feb-2018)

40.7 b

Cash (31-Dec-2017)

1.7 b
Vertex Pharmaceuticals's current market capitalization is $40.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.2 b580.4 m1 b1.7 b2.5 b

Revenue growth, %

(52%)78%65%

R&D expense

1 b1.3 b

Operating expense total

1 b2.4 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

221.7 m118.5 m138.4 m179 m138.5 m166.1 m309.8 m398.1 m431.6 m413.8 m714.7 m544.1 m

R&D expense

228.6 m239 m224.8 m190.9 m215.6 m223.9 m246.3 m255.9 m271 m272.4 m273.6 m289.5 m

Operating expense total

355.8 m334.8 m319.3 m321.2 m310.5 m337.2 m379.8 m412.4 m428.3 m432.5 m443.9 m491.4 m

EBIT

(134.1 m)(216.4 m)(180.8 m)(142.2 m)(172 m)(171.2 m)(70 m)(14.3 m)3.4 m(18.7 m)270.8 m52.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

569.3 m625.3 m714.8 m1.2 b1.7 b

Accounts Receivable

85.5 m76 m177.6 m201.1 m281.3 m

Inventories

14.1 m30.8 m57.2 m77.6 m111.8 m

Current Assets

1.6 b1.5 b1.4 b1.8 b2.6 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

583.2 m424 m420.6 m718.6 m664.9 m870.5 m756.3 m604.2 m605.9 m719.7 m1 b1.2 b

Accounts Receivable

120.3 m59.9 m81.8 m114.3 m80.3 m94.5 m165.3 m181.9 m189.4 m182.2 m208 m247.9 m

Inventories

13.5 m11.3 m12 m16.8 m34.1 m42.1 m49.2 m63.2 m66.6 m71.8 m82 m92.3 m

Current Assets

1.6 b1.4 b1.3 b1.7 b1.4 b1.3 b1.4 b1.4 b1.5 b1.5 b1.9 b2.2 b
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    (687.6 m)(742.7 m)(588.2 m)(84 m)91.6 m

    Depreciation and Amortization

    48.4 m63.3 m62.3 m61.4 m61.4 m

    Accounts Receivable

    53.4 m7.4 m(100 m)(33 m)(71.8 m)

    Inventories

    7.1 m(16 m)(23 m)(16.5 m)(45 m)
    USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

    Net Income

    (128.7 m)(232.5 m)(159.4 m)(198.7 m)(391.8 m)(561.9 m)(36.1 m)(72.3 m)(111.8 m)249.5 m(72.3 m)

    Depreciation and Amortization

    16.4 m31.4 m45.9 m14.9 m

    Accounts Receivable

    94.5 m165.3 m(2.5 m)(13 m)(9.8 m)(5.1 m)

    Inventories

    42.1 m49.2 m(4.8 m)(7.8 m)(11.5 m)(3.7 m)
      USDY, 2017

      Revenue/Employee

      1.2 m

      Financial Leverage

      1.7 x
      Show all financial metrics

      Vertex Pharmaceuticals Market Value History

      Vertex Pharmaceuticals's Web-traffic and Trends

      Vertex Pharmaceuticals Online and Social Media Presence

      Vertex Pharmaceuticals Company Life and Culture

      You may also be interested in